JPRN-UMIN000014625
Completed
未知
For advanced or recurrent esophageal cancer Of combination therapy - docetaxel-cisplatin-5 fluorouracil phase I/II trial - Bi-weekly DCF therapy for esophageal cancer PI/II study
ConditionsAdvanced or recurrent esophageal cancer
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Advanced or recurrent esophageal cancer
- Sponsor
- gifu University
- Enrollment
- 30
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Cases with (heart disease, interstitial pneumonitis or pulmonary fibrosis, and cirrhosis of the liver) complications serious. patients with serious infections Patients with edema required Treatment Cases with non\-pleural effusion control, ascites Patients with a history of drug hypersensitivity serious. Cases there is a possibility that pregnant women, pregnant and lactating women. Cases is determined participation in the test is difficult and complicated by psychiatric symptoms or psychosis Patients undergoing (oral or intravenous) systemic continuous administration ofsteroid Cases attending physician was deemed inappropriate In carrying out Other, this clinical trial.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 3
Management of advanced esophageal cancer patients received chemotherapy using early ctDNA dynamicsEsophageal cancerJPRN-UMIN000047559Division of Biomedical Research and Development, Institute of Biomedical Sciences, Iwate Medical University60
Not yet recruiting
Not Applicable
Prospective Multicenter Observational Study of Esophageal Preservation Survival in definitive Chemoradiotherapy +/- Photodynamic Therapy for Esophageal CancerEsophageal CancerJPRN-UMIN000043767agoya University150
Completed
Not Applicable
Study of treatment for esophageal cancerEsophageal cancerJPRN-UMIN000040909Graduate School of Medical Sciences,Kyushu University26
Not yet recruiting
Not Applicable
Clinical Outcomes in patients with Esophageal Cancer treated with Definitive ChemoradiotherapyHealth Condition 1: C159- Malignant neoplasm of esophagus, unspecifiedCTRI/2021/03/032343one
Not yet recruiting
Phase 1
Juzendaihoto administration for esophageal cancer patientsEsophageal cancerJPRN-UMIN000036616agasaki University35